



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38163-0061

Applicant: Jeffrey SCHLOM et al.

Confirmation No.: 8846

Appl. No.: 09/155,590

Examiner: CANELLA, Karen A.

Filing Date: September 30, 1998

Art Unit: 1643

Title: MUTATED RAS PEPTIDES FOR GENERATION OF CD3+
CYTOTOXIC T LYMPHOCYTES

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on the attached Form PTO/SB/08A is a document known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56. A copy of the listed document is being submitted to comply with the provisions of 37 C.F.R. §1.97-§1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

01/27/2006 JADD01 00000088 09155590

02 FC:1806

180.00 0P

TIMING/FEE

The instant Information Disclosure Statement is being filed after the mailing of a final action under §1.113, but before the mailing date of a notice of allowance under §1.311. The required fee in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached. The Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

RELEVANCE

Each document (B01-B13) is relevant to the enablement of the claimed invention and is discussed separately in the Office Action Response filed January 26, 2006.

Applicants respectfully request that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: January 26, 2006

By Patricia D. Granados

HELLER EHRMAN LLP
1717 Rhode Island Avenue, NW
Washington, DC 20036-3001
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

Patricia D. Granados
Attorney for Applicant
Registration No. 33,683
Customer No. 44991



PTO/SB/08B (08-03)

Approved for use through 07/31/06. OMB 0651-0031
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/155,590
				Filing Date	September 30, 1998
				First Named Inventor	Jeffrey SCHLOM et al.
				Art Unit	1643
				Examiner Name	CANELLA, Karen A.
Sheet	1	of	2	Attorney Docket Number	38163-0061

NON PATENT LITERATURE DOCUMENTS						
Examiner initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	B01	Carbone DP, Ciernik IF, Kelley MJ et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. <i>J Clin Oncol</i> 2005;23:5099-107.				
	B02	Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. <i>J Clin Invest</i> 2004;113:1515-25.				
	B03	Gilboa E. The promise of cancer vaccines. <i>Nat Rev Cancer</i> 2004;4:401-11.				
	B04	Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. <i>Cancer Res</i> 2005;65:8059-64.				
	B05	Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. <i>Nat Rev Cancer</i> 2003;3:666-75.				
	B06	Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. <i>Nat Rev Cancer</i> 2005;5:275-84.				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,



PTO/SB/08B (08-03)

Approved for use through 07/31/06. OMB 0651-0031
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/155,590
				Filing Date	September 30, 1998
				First Named Inventor	Jeffrey SCHLOM et al.
				Art Unit	1643
				Examiner Name	CANELLA, Karen A.
Sheet	2	of	2	Attorney Docket Number	38163-0061

NON PATENT LITERATURE DOCUMENTS						
Examiner initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				² T
	B07	Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. <i>Cancer Cell</i> 2004;6:117-27.				
	B08	Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. <i>Science</i> 2002;298:850-4.				
	B09	Bos JL. ras oncogenes in human cancer: a review. <i>Cancer Res.</i> 1989;49:4682-89.				
	B10	Abrams SI, Hand PH, Tsang KY, Schlom J. Mutant ras epitopes as targets for cancer vaccines. <i>Semin. Oncol.</i> 1996;23:118-34.				
	B11	Fossum B, Gedde-Dahl I, T. , Breivik J et al. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp). <i>Int. J. Cancer</i> 1994;56:40-5.				
	B12	Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA. Quantitating therapeutically relevant T-cell responses to cancer vaccines. <i>Crit Rev Immunol</i> 2001;21:287-97.				
	B13	Linard B, Bezieau S, Benlalam H et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. <i>J Immunol</i> 2002;168:4802-8.				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public